Medroxyprogesterone is a progesterone receptor agonist (Ki= 241 nM) and a metabolite of medroxyprogesterone 17-acetate. It induces a conformational change in the C-terminal domain of the progesterone receptor (EC50 = 47.3 nM) and increases alkaline phosphatase activity in T47D breast cancer cells (EC50 = 23 nM).